1 Polygenic risk for Alzheimer's disease predicts sleep slow-waves and daytime

- 2 sleepiness in youth
- 3
- 4 Short title: Linking Alzheimer's disease to sleep in youth
- 5

Vincenzo Muto^{1,2#}, Ekaterina Koshmanova^{1#}, Pouya Ghaemmaghami^{1#}, Mathieu Jaspar^{1,2,3},
Christelle Meyer^{1,2}, Mahmoud Elansary⁴, Maxime Van Egroo¹, Daphne Chylinski¹, Christian
Berthomier⁵, Marie Brandewinder⁵, Charlotte Mouraux¹, Christina Schmidt^{1,2}, Grégory
Hammad¹, Wouter Coppieters⁴, Naima Ahariz⁴, Christian Degueldre¹, André Luxen¹, Eric
Salmon^{1,3,6}, Christophe Phillips^{1,7}, Simon N. Archer⁸, Loic Yengo¹⁰, Enda Byrne¹⁰, Fabienne
Collette^{1,3}, Michel Georges⁴, Derk-Jan Dijk^{8,9}, Pierre Maquet^{1,2,6}, Peter M. Visscher¹⁰, Gilles
Vandewalle^{1*}

13

14 Affiliations:

- ¹GIGA-Cyclotron Research Centre-In Vivo Imaging, University of Liège, Liège, Belgium.
- ² Walloon Excellence in Life sciences and Biotechnology (WELBIO, Belgium).
- ³ Psychology and Cognitive Neuroscience Research Unit, University of Liège, Liège, Belgium.
- ⁴GIGA-Medical Genomics, University of Liège, Liège, Belgium.
- ⁵ Physip, Paris, France.
- ⁶ Department of Neurology, University Hospital of Liège, Liège, Belgium.
- 21 ⁷ GIGA-In Silico Medicine, University of Liège, Liège, Belgium.
- ⁸ Sleep Research Centre University of Surrey, University of Surrey, Guildford.
- 23 ⁹ UK Dementia Research Institute.
- ¹⁰ Institute for Molecular Bioscience, University of Queensland, Brisbane, Australia.
- 25
- [#] These authors contributed equally to this work
- 27

* Correspondence to: Gilles Vandewalle, GIGA-Cyclotron Research Centre-In Vivo Imaging,
 Bâtiment B30, Allée du 6 Août, 8, 4000 Liège, Belgium, +3243662316,
 gilles.vandewalle@uliege.be

- 31
- 32
- 33

34 Abstract

A bidirectional detrimental relationship between sleep alteration and Alzheimer's disease 35 (AD) has been reported in cognitively normal older adults. Here, we tested whether a similar 36 association could be detected in young adults, decades before typical AD symptom onset. We 37 investigated associations between sleep endophenotypes and genome-wide Polygenic Risk 38 39 Scores (PRS) for AD in 363 young men (22.1±2.7y) devoid of sleep and cognitive disorders. AD PRS was associated with higher slow wave energy, a marker of sleep need, during habitual 40 41 sleep and following sleep loss, and, potentially, with the relative increase in slow wave energy following sleep deprivation, reflecting sleep homeostasis. Furthermore high AD PRS was 42 correlated with higher daytime sleepiness. These results imply that sleep features may be 43 44 associated with AD liability in young adults and suggest that, contrary to older adults, denser 45 and/or more intense sleep slow waves are associated with AD risk in early adulthood.

47 Introduction

Defective proteostasis of brain amyloid-beta (Aβ) and tau protein antedates the clinical manifestations of Alzheimer's disease by decades (Jack et al., 2018; Musiek and Holtzman, 2015; Scheltens et al., 2016). This so-called "preclinical" window constitutes an opportunity for internvention that would hopefully reduce the predicted increase in AD prevalence (Norton et al., 2014), despite the absence of disease modifying treatments in the foreseeable future. In this respect, the further identification of AD risk factors is of paramount importance.

54 Altered sleep has recently been related to increased risk for AD, over and above sleep disturbances in AD patients (Van Egroo et al., 2019). Longer latency to fall asleep and reduced 55 sleep slow waves and rapid eye movement (REM) sleep are associated with both A^β plaques 56 and Tau neurofibrillary tangles (NFTs) in cognitively normal participants (Branger et al., 2016; 57 58 Lucey et al., 2019; Mander et al., 2015). Sleep fragmentation and the reduction in REM sleep quantity in cognitively normal individuals aged >60 y predict the future risk of developing AD 59 (Lim et al., 2013; Pase et al., 2017). Acute sleep deprivation (Holth et al., 2019; Ooms et al., 60 2014), and experimentally induced reduction of sleep slow waves (Ju et al., 2017), increases 61 62 cerebrospinal fluid (CSF) A_β and Tau protein content.

63 In post mortem human brain tissues, the first signs of brain protein aggregation are identified in the locus coeruleus (LC), a brainstem nucleus essential to sleep regulation 64 65 (Mather and Harley, 2016), under the form of pretangles, consisting of phosphorylated Tau protein (Braak and Del Tredici, 2011). Critically, LC pretangles can be detected during 66 adolescence, while by age 30, they can be detected in the majority of the population (> 90%) 67 68 (Braak and Del Tredici, 2011). With age, Tau deposits increase in the brain in a stereotypical manner and are tightly associated with cognitive decline in overt 'clinical' AD (Braak and Del 69 70 Tredici, 2011). Individual variations in these intrinsic properties should be reflected in brain

function, including sleep, whether or not Tau aggregation has already occurred. Furthermore, although the consequences of LC pretangles are unknown (Mather and Harley, 2016), they might affect brain functions, including during sleep. Tau plays an important role in synaptic function while Tau pretangles and their surrounding soluble hyperphosphorylated Tau, which remain undetectable *in vivo* in humans, are suspected to have a deleterious impact on neuronal function (DeVos et al., 2013; Hall et al., 2015; Mondragón-Rodríguez et al., 2012; Pooler et al., 2014; Schultz et al., 2018).

78 We therefore reasoned that early associations between sleep and AD might exist in young healthy adults (i.e., before 30 y), especially because AD is heritable (Marioni et al., 79 2018). Sporadic AD, the most common form of AD in the general population, has an estimated 80 heritability ranging between 58% to 79% (Ertekin-Taner, 2010; Gatz et al., 2006). Individual 81 82 Polygenic Risk Scores (PRS) for AD can be computed based on results of published Genome Wide Association Studies (GWAS). These PRS reflect part of the genetic liability for AD in any 83 asymptomatic individual and, at the group level, can be associated with phenotypes of interest 84 which are related to the (risk) pathways leading to AD (Euesden et al., 2015; Ge et al., 2019). 85 Recent studies reported significant association between AD PRS and CSF AB content 86 87 (Martiskainen et al., 2015), cortical thickness (Sabuncu et al., 2012), memory decline (Marden et al., 2016), and hippocampus volume (Mormino et al., 2016) in cognitively normal older 88 89 adults (> 45 y) but, importantly, also in young adults (18 -35 y) (Mormino et al., 2016).

Here, we conducted a proof-of-concept study to establish that sleep can be related to AD risk in young adults, using PRS for AD. We phenotyped sleep under different conditions (baseline, sleep extension, recovery sleep after total sleep deprivation) in a homogenous sample of young healthy cognitively normal men without sleep disorders and computed individual PRS for AD. We hypothesized that high PRS would be associated with sleep metrics

that had previously been associated with AD features in cognitively normal older adults. We
further explored whether subjective assessments and behavioural correlates of sleep quality
would be associated with PRS for AD.

98

99 Results

100 Following 3 weeks of imposed regular sleep which was confirmed with actimetry, 363 healthy men aged between 18 and 31 y (Table 1) completed a 7-day protocol including 101 102 polysomnographically recorded sleep during habitual sleep-wake times (range of total sleep duration: 361 to 518 min), during a 12h extended sleep opportunity, and during a 12h recovery 103 sleep opportunity following 40h of total sleep deprivation (Figure 1). A blood sample was 104 105 collected in all participants to assess whole genome common single nucleotide 106 polymorphisms (SNPs). PRS were computed as the weighted sum of the effect sizes of the AD-107 associated SNPs, obtained from summary statistics of AD cases vs. controls GWAS (Euesden et al., 2015; Ge et al., 2019). PRS can indicate the presence of a genetic signal in moderate 108 109 sample size studies (Euesden et al., 2015; Sabuncu et al., 2012) as long as it is computed based 110 on a very large GWAS (Dudbridge, 2013; Santoro et al., 2018). We therefore used the summary 111 statistics of one of the largest AD-GWAS available to date (N = 388,324) (Marioni et al., 2018) 112 to compute individual PRS for AD in our sample and related these to sleep EEG characteristics 113 following multiple quality control steps (Supplementary Figure S1).

114

115 Polygenic risk for AD is associated with the generation of slow waves during sleep

116 We first focused on baseline sleep, as it is most representative of habitual sleep, to evaluate 117 sleep metrics that might be associated with AD liability. Given our sample size, we reduced 118 the multiple comparison burden by selecting *a priori* variables of interest among

119 electrophysiology sleep metrics that have previously been related to Aβ and Tau in cognitively 120 normal older adults: sleep onset latency [SOL] (Branger et al., 2016; Ettore et al., 2019), 121 duration of wakefulness after sleep onset [WASO] (Ettore et al., 2019), duration of REM sleep (Pase et al., 2017), slow wave energy [SWE] during NREM sleep (Lucey et al., 2019; Mander et 122 al., 2015), i.e. the cumulated power in the 0.5-4 Hz EEG band, and hourly rate of micro-arousal 123 124 during sleep (Ju et al., 2017). To compute PRS, one considers SNPs below a p-value threshold in the reference GWAS; the optimal threshold for SNP selection to best compute a PRS for AD 125 is not established. Previous studies employed very exclusive GWAS p-values (p~10⁻⁸) (Sleegers 126 et al., 2015) to more inclusive p-values (p = .5) (Escott-Price et al., 2015; Mormino et al., 2016), 127 leading to the inclusion of effect sizes of a few tens to hundreds of thousands SNPs to compute 128 129 AD PRS. We opted for computing PRS based on increasingly inclusive p-value thresholds (including SNPs reaching GWAS significance $-p < 5x10^{-8}$ - to very liberal p < 1), whilst also 130 pruning SNPs based on their correlation structure (i.e. linkage disequilibrium) (Supplementary 131 Table S1) (Escott-Price et al., 2015; Mormino et al., 2016). In addition, we performed a PRS 132 analysis using all SNPs without any selection. 133

General linear model (GLM) analyses controlling for age, body mass index (BMI) and 134 135 total sleep time (TST), reveal an significant association between baseline night SWE and AD PRS (p <0.02; $\beta \ge 0.12$) from a p-value threshold of p=0.05 up to selecting all SNPs; the 136 137 association reached stringent experiment-wise correction for multiple comparisons when selecting all SNPs (p < 0.00125, see methods; $\beta = 0.17$; Figure 2A; Supplementary Table S2). 138 139 We performed a negative control analysis using a PRS for height, a variable for which no 140 association with sleep metrics was expected, and found no association (Supplementary Figure 141 S2A). The association between AD PRS and SWE was positive (Figure 2B) indicating that higher 142 SWE was associated with higher AD-PRS. SWE was also positively associated with TST (Supplementary Table S2), which was expected since TST conditions the opportunity to generate slow waves, and negatively with age, which is in line with the literature (Carrier et al., 2011) but may still be surprising given the young age of our sample. Importantly, since GLM included TST and age, they are not driving the association we find between SWE and PRS for AD.

148 Sleep onset latency (SOL) also reached significant association with AD PRS from a p-149 value threshold of p=0.05 up to p = 1 (p \leq 0.04; β = -0.11), but significance did not reach 150 stringent experiment-wise correction for multiple comparisons (p < 0.00125) (Figure 2A; Supplementary Table S2). Hence, this result has to be considered with caution and will not be 151 extensively commented upon. It is interesting to note, however, that the association between 152 153 PRS for AD and SOL is negative, with higher PRS associating with shorter sleep latency (Figure 154 **2C**). Of note, REM% reached uncorrected significance (p < 0.05) for thresholding at p=0.05 (β = 0.1), with a positive association with AD PRS (Figure 2A; Supplementary Table S2), but, since 155 it is observed for only one p-value threshold, this will not be discussed any further. 156

These results indicate that, particularly when considering all SNPs to construct the AD 157 158 PRS, the overnight power of the slow waves generated during Non-REM sleep, which is a 159 widely accepted measure of sleep need (Dijk and Czeisler, 1995), is linearly and positively associated with AD genetic liability. This finding suggests that individuals with a higher genetic 160 161 liability for AD have a higher need for sleep. This idea is further reinforced by the fact that 162 association between SWE and AD PRS is also significant when only considering SWE of the first 163 hour of sleep (Dijk and Czeisler, 1995) (Supplementary Figure S3 & Table S3), and the 164 potential negative association with SOL, which depends in part on sleep need.

Since slow oscillations (SO), i.e. EEG slow waves < 1 Hz, may be distinct from faster slow
 waves (Steriade and Amzica, 1998), we further decomposed SWE into SO-SWE (0.5-1Hz) and

faster-oscillations—SWE (FO-SWE; 1.25 – 4 Hz). Both SO-SWE and FO-SWE were similarly and
significantly associated with AD PRS and for the same p-value thresholds (Figure 2D;
Supplementary Table S3). The association we found between SWE and AD PRS does not
appear therefore to arise exclusively from either slower or faster slow waves.

171

172 Recovery sleep, slow wave sleep rebound and extension night

When considering sleep EEG of the other nights, we only included SWE, as it is the only sleep 173 174 metric that was associated with PRS for AD at stringent correction for multiple comparisons threshold. Similarly to baseline night, when considering SWE during the recovery night that 175 followed total sleep deprivation, GLM including age, BMI and TST, reveal that SWE and AD PRS 176 177 are significantly associated ($p \le 0.04$; $\beta \ge 0.11$) from p-value thresholding at p=0.1 up to using 178 all SNPs (Figure 3A; Supplementary Table S4), and the association reached stringent experiment-wise correction for multiple comparisons at p-value threshold of p=1 (p < 179 0.00625). Again, the association was positive with higher SWE associated with higher AD PRS 180 (Figure 3B) and results were similar when considering only SWE of the first hour of sleep 181 182 (Supplementary Figure S3 & Table S4). Individuals typically produce more sleep slow waves 183 in response to sleep loss, as part of the homeostatic regulation of sleep (Klerman and Dijk, 2005). Therefore, individuals with higher need for sleep after sleep loss have a high PRS for 184 185 AD.

Slow wave sleep rebound quantifies the physiological response to a lack of sleep based on the relative changes from normal sleep to recovery sleep following sleep loss. We computed the ratio between the initial SWE (1h of sleep) during recuperation and baseline nights to assess SWE rebound. GLM analysis, including age and BMI, indicated that SWE rebound reached significant association with AD PRS when including all SNPs (β = -0.11), but

191 significance did not reach stringent experiment-wise correction for multiple comparisons (p < 0.00625) (Figure 3A; Supplementary Table S4). Sleep rebound is driven by sleep homeostasis 192 which tightly regulates sleep duration and intensity based on prior sleep-wake history (Dijk 193 and Landolt, 2019). Since we observe an association with AD PRS for a single p-value threshold 194 at uncorrected p-value our findings suggest that, in our sample, AD PRS was not tightly 195 196 associated with sleep homeostatic response. Interestingly though, Spearman's correlation indicated that SWE rebound was correlated to SWE during the recovery night (r = 0.39, p $<10^{-10}$ 197 ¹⁴; Figure 3C). 198

We then considered SWE during the extension night and PRS for AD in a GLM, including 199 age, BMI and TST. Results indicated that extension night SWE was not significantly linked to 200 201 AD PRS. This may be because sleep timing for this particular night affects sleep quality (Dijk 202 and Landolt, 2019; Dijk and Czeisler, 1995) (Figure 3A). In contrast to baseline and recuperation sleep periods which were initiated at habitual sleep time, sleep extension started 203 2 hours before habitual sleep time, covering the end of a period known as the evening "wake-204 205 maintenance zone" corresponding to the time at which the circadian system maximally 206 promotes wakefulness (Dijk and Czeisler, 1995). In addition, the circadian system is known to 207 affect the relative content in Non-REM and REM sleep as well as in different EEG frequencies 208 (Dijk and Landolt, 2019; Dijk and Czeisler, 1995). Therefore, the imposed 2h advance of sleep 209 time during the extension night affected sleep quality, which may have reduced the association between SWE and AD PRS found with baseline and recovery nights. 210

211

212 Polygenic risk for AD is associated with increased subjective daytime sleepiness

213 We next focused on the non-EEG sleep metrics of our protocol and explored their potential 214 association with AD PRS. Based on the 3 weeks of actigraphy with imposed regular habitual

sleep time at home, we computed the probability of transition from rest to activity during the sleep period [kRA; (Lim et al., 2013)]. kRA is a proxy for sleep fragmentation and has been associated with cognitive decline and the risk for developing AD in cognitively normal older adults [mean age 81.6 y (Lim et al., 2013)]. kRA showed a negative association (higher AD PRS is associated with less fragmented sleep) with PRS for AD for two p-value thresholds, p=5 x 10⁻⁸ and p = 10^{-8} (Figure 4A; Supplementary Table S5), but did not reach stringent experimentwise correction for multiple comparisons (p < 0.002); it will not be further discussed.

222 Two questionnaires assessed habitual subjective sleep quality and daytime sleepiness 223 before the start of the protocol. Subjective sleep quality was not significantly associated with AD PRS. By contrast, subjective daytime sleepiness was significantly associated with PRS for 224 225 AD (p < 0.05; $\beta \ge 0.11$) from thresholding at p < 10⁻⁴ up to a threshold of p < 1 and at stringent 226 experiment-wise correction for multiple comparisons at p-value thresholds of p < 0.05 and p < 0.3 (p < 0.002, see methods; $\beta \ge 0.16$; Figure 4A; Supplementary Table S5). The association 227 was positive indicating that higher habitual subjective daytime sleepiness was associated with 228 229 higher AD PRS (Figure 4B). This shows that the association between AD PRS and sleep need, as assessed by electrophysiology, is not a mere effect of the protocol and is mirrored at the 230 231 behavioural level during habitual daytime functioning (outside the experimental protocol). 232 Importantly the vast majority of participants had no or mild levels of sleepiness with a minority 233 (N = 28) reporting moderate level of daytime sleepiness; the association with daytime sleepiness is therefore not driven by extreme or clinically relevant sleepiness levels but rather 234 235 by ordinary variability in healthy young individuals.

236

238 Discussion

239 We provide evidence that genetic liability for AD is related to sleep characteristics and daytime 240 sleepiness in young adults (aged 18 to 31 y), i.e. decades before typical onset age of clinical AD symptoms and at an age at which current AD biomarkers are typically negative. Our sample 241 size is modest for the detection of small effect size associations, so the present results should 242 243 be considered as a proof-of-concept for linking AD liability and sleep in young adults. We emphasize, however, that the unique deep phenotyping of our protocol in hundreds of 244 245 participants, based on gold standard electrophysiology and comprising different sleep conditions, undoubtedly increased the sensitivity of our analyses so that we could find 246 associations that survived stringent correction for multiple comparisons. Importantly, our 247 248 protocol provides links between disease risk and sleep physiology in contrast to coarser 249 phenotyping based on sleep questionnaires or actimetry alone. The characteristics of our sample renders our findings remarkable: to increase the genetic uniformity of the sample we 250 only included Caucasian men within a narrow age range; they were healthy and devoid of any 251 sleep disorders or sleep complaints and their prior sleep-wake history was recorded and 252 253 stable. In this carefully selected homogenous sample, higher PRS for AD was associated with 254 producing denser or larger slow waves during baseline and recovery night time sleep, 255 potentially with large slow wave sleep rebound following sleep deprivation, and with 256 reporting higher daytime sleepiness.

Larger and more abundant slow waves during habitual sleep in young and healthy individuals can result from an increased sleep need due to insufficient prior sleep (Klerman and Dijk, 2005). This appears unlikely: prior sleep-wake history was stringently controlled for weeks prior to entering the lab, ruling out undue sleep deprivation, sleep restriction or disrupted rhythmicity. Moreover, throughout the protocol, participants followed their own

262 sleep schedule, a regime that should not expose them to important chronic sleep restriction. Finally, SWE during the sleep extension night did not significantly correlate with subjective 263 264 daytime sleepiness (Spearman's correlation r = 0.08, p = 0.11), supporting the idea that, when given a longer sleep opportunity, individuals with higher and yet normal daytime sleepiness 265 did not sleep more intensely to recover a putative prior sleep debt. Alternatively, increased 266 267 slow wave density and/or intensity could reflect a faster build-up of sleep need (Viola et al., 2007). Indeed, sleep homeostasis is thought to result from molecular and cellular changes 268 269 induced by waking brain function and behaviour (Scammell et al., 2017; Tononi and Cirelli, 2014). Synaptic potentiation and increased synaptic strength resulting from waking 270 experience are reflected in a progressive increased cortical excitability during wakefulness 271 272 (Huber et al., 2013; Ly et al., 2016) and an increase in slow wave activity during subsequent 273 sleep (Scammell et al., 2017; Tononi and Cirelli, 2014). Likewise, extracellular glutamate concentration and glutamatergic receptor density increase with time awake and affect brain 274 function (Dash et al., 2009; Hefti et al., 2013). Here, SWE rebound following sleep loss, i.e. the 275 276 ratio between baseline and recovery sleep, was only significantly associated with high PRS for AD for one p-value threshold and at uncorrected significance threshold, but was strongly 277 278 associated with SWE during recovery sleep. We therefore find only partial evidence for this 279 second hypothesis, which will require more investigations.

How are these findings related to AD? The answer to this question remains speculative because the time course of AD processes across lifespan is still poorly understood. In transgenic mice, neuronal activity locally increases the level of A β in the interstitial fluid and drives local A β aggregation (Bero et al., 2011). The progressive A β deposition ultimately disrupts local functional connectivity and increases regional vulnerability to subsequent A β deposition (Bero et al., 2012). We might thus hypothesize that individuals with more intense

286 brain activity during wakefulness (and therefore also during sleep) would also be exposed to larger AB extracellular levels and a greater risk of developing AB deposits. This hypothesis 287 appears unlikely for the following reasons. First, post mortem examinations show that the 288 earliest evidence of Aβ deposits (stage 1 (Thal et al., 2002)) is not observed before 30 y (Braak 289 and Del Tredici, 2015). Second, Aß oligomers might be released and exert their detrimental 290 291 effect on brain function at an earlier age. However, in transgenic mice, sleep-wakefulness cycle and diurnal fluctuation in brain extracellular Aß remain normal until plaque formation 292 293 (Roh et al., 2012).

By contrast, given the age range of our population sample, the reported topography of 294 pretangles at this age (Braak and Del Tredici, 2011) and the power of PRS for AD to 295 296 discriminate AD patients in case-control samples (Escott-Price et al., 2015), higher PRS in our 297 young sample might reflect the influence of incipient Tau aggregation onto sleep regulation through the LC (and other non-thalamic cortically-projecting nuclei, as raphe nuclei) (Braak 298 299 and Del Tredici, 2011). Tau, an intracellular protein, is also detected in the extracellular space. 300 Over and above a low level constitutive tau secretion (Chai et al., 2012), neuronal activity increases the release of tau in the extracellular space (Yamada et al., 2014), thereby 301 302 participating in enhancing tau spread and tau pathology in vivo (Schultz et al., 2018). 303 Moreover, early electrophysiological changes indicative of hyperexcitability are observed in 304 intact neurons from transgenic tau mice (Crimins et al., 2012). In the cerebral cortex of tau 305 transgenic mice, glutamatergic and GABAergic neurons are in a hypermetabolic state, 306 characterized by a relative increase in production of glutamate (Nilsen et al., 2013). By 307 contrast, decreasing tau in epilepsy-prone transgenic mice reduces neuronal hyperexcitability 308 (Holth et al., 2013). These findings would suggest that a strong cerebral activity during 309 wakefulness would result in a higher daily average in perceived sleepiness, a substantial tau

release and an enhanced sleep homeostasis processes, as indicated by denser and larger slowwaves.

The reasons for the vulnerability of LC to Tau aggregation are not established but might 312 reside in its constant recruitment for essential functions, its energy demanding and ubiquitous 313 314 brain connections, its high vascularization or its higher susceptibility to oxidative stress 315 (Mather and Harley, 2016). Although it tantalizing to hypothesize that tau is involved in the 316 mechanisms linking slow wave sleep and AD liability, one can also speculate that it is the LC 317 intrinsic characteristics that are related to tau vulnerability (subsequent) that associated with PRS for AD, meaning that the association would not necessarily require the presence of tau to 318 be detected. 319

320 On the other hand, in tau transgenic mice, misfolded and hyperphosphorylated tau 321 alters hippocampal synaptic plasticity (Polydoro et al., 2014), eventually induces a loss of hippocampal LTP and causes reduction of synaptic proteins and dendritic spines (Van der 322 Jeugd et al., 2012) (Sydow et al., 2011). These findings would predict a lower sleep need in 323 participants with high AD liability. However, it is possible that these detrimental processes 324 325 take place later on in the development of the disease or emerge from an interaction between 326 tau and Ab (Oddo et al., 2003) (Fein et al., 2008). Accordingly, in older adults, significant 327 associations, opposite to the current findings, were observed between slow wave sleep and 328 risk for AD based on PET biomarkers (Lucey et al., 2019; Mander et al., 2015): higher AB (Mander et al., 2015) or tau (Lucey et al., 2019) burdens were associated with lower sleep 329 330 slow wave EEG power. Our results suggest therefore that the association between AD risk and 331 sleep homeostasis changes with age: at an early stage, dense and large slow waves would be 332 associated with increased AD risk. Later on, the ability to generate slow waves would play a

protective role against AD risk. Deep sleep phenotyping across all ages and/or in long term
longitudinal studies will have to test this hypothesis.

We emphasize that the cross sectional nature of our study, precludes any causal 335 interpretation of the association we find between AD and sleep. We further stress that our 336 sample only include men and cannot therefore be extended to the entire population. Women 337 338 have been reported to have different sleep characteristics, including the production of more 339 numerous and intense slow waves during sleep (Svetnik et al., 2017). It is also worth 340 mentioning that we cannot isolate in our findings the specific contributions of the circadian timing system, which is the second fundamental mechanism regulating sleep and wakefulness 341 (Dijk and Landolt, 2019). Although we find significant association between AD PRS and 342 baseline/recovery SWE and daytime sleepiness across similar p-value thresholds, more 343 344 research is also required to determine how many SNPs one has to include, i.e. what SNP selection strategy should be used to best predict AD. Previous studies support that using a 345 lenient p-value thresholds is successful in doing so (Escott-Price et al., 2015; Mormino et al., 346 347 2016), thus we are confident that our finding are related to AD liability. Our PRS calculation was stringently controlled for the weight of chromosome 19 (see methods) to avoid excessive 348 349 contribution from Apolipoprotein E (APOE) genotype, which is the genetic trait most associated with sporadic AD. When comparing APOE ɛ4 carriers genotype vs. non-carriers, no 350 351 significant difference in baseline night SWE and daytime sleepiness was observed 352 (Supplementary Figure S4), in line with our findings that a large number of SNPs is required 353 to find an association between SWE and PRS for AD.

The specificity of our findings for a given EEG frequency band and/or for NREM remains to be fully established. As many previous studies on linking sleep and AD risk [e.g. (Lucey et al., 2019; Mander et al., 2015)], we only focussed on a limited set of sleep metrics, and

357 included a single power measure over a given frequency band. Although not the focus of the 358 present paper, we computed SWE, relative SWE (i.e. ratio between SWE and overnight total 359 NREM power), overnight cumulated total power during NREM sleep and overnight cumulated power in the 2 to 6 Hz band during REM sleep of the baseline night in individuals among the 360 higher and lower AD PRS quartile (Supplementary Figure S5). This simple analyses indicates 361 362 that individuals with 25% highest AD PRS had higher power than individuals with 25% lowest AD PRS for all three absolute measures (t-test; $p \le 0.01$ but not for relative SWE (p = 0.14), 363 364 suggesting that our findings may not be specific to NREM sleep and SWE. We emphasize, however, that, given our modest sample size, our analyses was not planned to address such 365 question. This first preliminary analysis warrants future studies with larger sample size 366 367 ensuring sufficient power when using a larger set of sleep metrics. Since we also find that 368 daytime sleepiness, a wakefulness trait, is associated with PRS for AD, and because of the link between tau protein and cortical excitability (Holth et al., 2013), neuronal activity synchrony 369 during wakefulness should be associated with the risk for developing AD to assess whether 370 371 isolated links are specific to sleep.

In conclusion, we find that denser and/or more intense sleep slow waves during 372 373 baseline and recovery sleep and daytime sleepiness are associated with the genetic liability 374 for AD in young and healthy young men. This finding supports that sleep slow wave and 375 sleepiness measures may help early detection of an increased risk for AD and reinforce the 376 idea that sleep may be an efficient intervention target for AD. Similarly to most studies 377 associating PRS to phenotypes of interest [e.g. (Marden et al., 2016; Mormino et al., 2016; 378 Sabuncu et al., 2012; Santoro et al., 2018)], the effects we isolated constitute relatively small 379 effects (r < 0.2), however, recalling that sleep must be envisaged within the multifactorial 380 aspect of a complex disease such as AD (Norton et al., 2014).

381 Materials and Methods

382 Participants

Three hundred and sixty-four young healthy men (aged 18-31 years) were enrolled for the study after giving their written informed consent, and received a financial compensation. This research was approved by the Ethics Committee of the Faculty of Medicine at the University of Liège, Belgium.

Exclusion criteria were as follows: Body Mass Index (BMI) > 27; psychiatric history or 387 388 severe brain trauma; addiction, chronic medication affecting the central nervous system; smoking, excessive alcohol (> 14 units/week) or caffeine (> 3 cups/day) consumption; shift 389 work in the past year; transmeridian travel in the past three months; moderate to severe 390 391 subjective depression as measured by the Beck Depression Inventory (BDI)(Beck et al., 1988) 392 (score > 19); poor sleep quality as assessed by the Pittsburgh Sleep Quality Index (PSQI) (Buysse et al., 1989) (score > 7). Participants with sleep apnea (apnea hypopnea index > 393 15/hour; 2017 American Academy of Sleep Medicine criteria, version 2.4) were excluded 394 395 based on an in-lab screening night of polysomnography. One participant, part of a twin pair, 396 was excluded from the analyses so that the analysed sample included 363 participants (Table 397 1). EEG recordings were missing due to technical issues for three of the five participants per nights of sleep considered in this manuscript. No individual had more than one night of sleep 398 399 missing so that all 363 individuals contributed to at least part of the analyses reported here. 400 The Epworth Sleepiness Scale (Johns, 1991) was used to characterize daytime sleepiness but 401 was not used for inclusion. While most participants scored normal values (\leq 11), 28 402 participants had scores ranging from 12 to 15, corresponding to moderate daytime sleepiness. 403 Because of an initial error in automatic evaluation of computerized questionnaires, seven 404 participants had PSQI scores higher than cut-off (scores of 8 or 9). No participants were,

405 however, taking sleep medication. To avoid reducing sensitivity, these participants were
406 included in all analyses but removing them did not change statistical outcomes.

407 Although available in our laboratory, Ab- and tau- PET scans were not conducted in 408 participants: it was felt unethical to expose them to an irradiation while results would 409 necessarily be normal.

410 Experimental Protocol

Individual sleep-wake history was strictly controlled: during the three weeks preceding the inlab experiment, participants were instructed to follow a regular sleep schedule according to
their habitual sleep timing (+/-30 min for the first 2 weeks; +/- 15 min for the last week).
Actigraphy data showed that included participants faithfully followed the assigned schedules.

Figure 1 provides an overview of the protocol. On Day 1, a urine drug test was 415 performed (10-multipanel drug) before completing an adaptation night at habitual 416 417 sleep/wake schedule during which a full polysomnography was recorded in order to screen for sleep related breathing disorders or periodic limb movements. On Day 2, participants left 418 419 the lab with the instruction not to nap (checked with actigraphy). They returned to the laboratory at the end of Day 2, completed a baseline night of sleep under EEG monitoring at 420 421 habitual sleep/wake schedule and remained in the laboratory until Day 7 under constant 422 CCTV. A 12h sleep extension night under EEG and centered around habitual sleep mid-point 423 was initiated on Day 3, in complete darkness with the instruction to try to sleep as much as 424 possible. Day 4 included a 4h afternoon nap under EEG recording (centred 1h after the mid-425 point between morning wake-up time and evening sleep time) further dissipated any residual 426 sleep need. What we termed the "before" night was also initiated on Day 4. It consisted in 8h sleep opportunity starting at habitual sleep time. During Day 5 and 6, participants remained 427 awake for 40 hours under constant routine (CR) conditions [dim light < 5 lux, semi-recumbent 428

position, 19°C ± 1, regular isocaloric food intake] before initiating a 12h recuperation night
from habitual sleep time until 4h after habitual wake time. Except during sleep (darkness – 0
lux) and constant routine protocol (dim light < 5 lux), participants were maintained in normal
room light levels oscillating between 50 and 1000 lux depending on location and gaze.
Analyses of "before" night, nap and sleep deprivation protocol will be reported elsewhere.
The current study focusses on baseline, extension and recovery nights of sleep.

435 **EEG acquisitions and analyses**

Sleep data were acquired using Vamp amplifiers (Brain Products, Germany). The electrode 436 montage consisted of 10 EEG channels (F3, Fz, F4, C3, Cz, C4, Pz, O1, O2, A1; reference to right 437 438 mastoid), 2 bipolar EOGs, 2 bipolar EMGs and 2 bipolar ECGs. Screening night of sleep also included respiration belts, oximeter and nasal flow, 2 electrodes on one leg, but included only 439 Fz, C3, Cz, Pz, Oz and A1 channels. EEG data were re-referenced off-line to average mastoids. 440 441 Scoring of sleep stages was performed automatically in 30-s epochs using a validated algorithm (ASEEGA, PHYSIP, Paris, France) (Berthomier et al., 2020) and according to 2017 442 443 American Academy of Sleep Medicine criteria, version 2.4. An automatic artefact detection algorithm with adapting thresholds (Wallant et al., 2016) was further applied on scored data. 444 Power spectrum was computed for each channel using a Fourier transform on successive 4-s 445 bins, overlapping by 2-s., resulting in a 0.25 Hz frequency resolution. The night was divided 446 447 into 30 min periods, from sleep onset until lights on. For each 30 min period, slow wave energy 448 (SWE) was computed as the sum of generated power in the delta band (0.5 - 4 Hz range)449 during all the NREM 2 (N2) and NREM 3 (N3) epochs of the given period, after adjusting for 450 the number of N2 and N3 epochs to account for artefacted data (Skorucak et al., 2018). As the frontal regions are most sensitive to sleep-wake history (Schmidt et al., 2012), SWE was 451 considered over the frontal electrodes (mean over F3, Fz, F4). To deal with the multiple 452

453 comparison issue, we did not consider SWE over the other parts of the scalp (Dijk and Landolt,
454 2019). Additional analyses also considered cumulative power between 0.5 and 25 Hz during
455 NREM and cumulative power between 2 to 6 Hz power during REM sleep as well through
456 similar computation procedures.

457 Genotyping and Imputation

Blood sample were collected on Day 2 for DNA analyses. The genotyping was performed using 458 459 the Infinium OmniExpress-24 BeadChip (Illumina, San Diego, CA) based on Human Build 37 (GRCh37). Missingness of the SNP markers were below 20% in all individuals. Using PLINK 460 software (Purcell et al., 2007), we excluded the SNPs with a minor allele frequency (MAF) 461 462 below 0.01, or Hardy-Weinberg disequilibrium (HWD) significance below 10⁻⁴. Markers with ambiguous alleles (A-T, T-A, G-C, C-G) were excluded as well. We finally ended with 511,729 463 SNPs. To investigate the relatedness between the individuals, using PLINK --genome 464 465 command, we computed the identity by descent (IBD) estimates for all pairs of individuals. For 8 pairs, the composite pi-hat score was between 0.15 and 0.56 suggesting the existence 466 467 of at least 3rd degree relatives in our cohort. However, we did not exclude any individuals at this level of analysis. We merged our cohort with "1000 Genomes Project" (Altshuler et al., 468 2010) and employed principal component analyses (PCA) on the merged samples to see if our 469 cohort was located in the European cluster (Figure S1A). We further assess allele frequencies 470 471 coherence of our cohort with the European subset of "1000 Genomes Project" (Figure S1B). 472 Markers with allele frequencies deviating more than 0.2 unit from European allele frequency 473 were excluded (Figure S1C). Genotype imputation was performed using "Sanger imputation server" by choosing "Haplotype Reference Consortium (release 1.1)" (HRC) as Reference Panel 474 475 and the Pre-phasing algorithm EAGLE2. Post-imputation QC was then performed very similarly to the one of above (MAF < 0.01, HWD < 10^{-4} , imputation quality score < 0.3). As a result of 476

such filters, 7,554,592 variants remained for the analysis. However, to avoid having markers
with allele frequencies deviating from European allele frequency, we computed the allele
frequencies for the samples in our cohort after imputation and cross checked them with the
European allele frequency (obtained from HRC Reference Consortium (release 1.1)) (Figure
S1D). The markers whose allele frequencies were deviating more than 0.2 unit from European
allele frequency were excluded.

483 **Predicting Height**

To validate common SNP assessments in our sample we predicted actual height based on 484 Polygenic Scores computed based on a meta-analysis of a recent GWAS study (Yengo et al., 485 486 2018) on around 700,000 individuals. We used all the variants in the meta-analysis that were included in our cohort [3121 SNPS out of 3290]. The procedure for calculating the Liability for 487 height is the same as the one described in the following section. Figures S1E visualize the 488 489 Pearson correlation results between the actual values for Height and estimated genetic Liability of Height (r = 0.46, p = 10^{-20}). Explained variance is very close to that reported 490 491 previously (Yengo et al., 2018), i.e. is 24.6%.

492 Polygenic Risk Score (PRS)

Polygenic risk score (PRS) is defined as the sum of multiple single-nucleotide polymorphism alleles associated with the trait for an individual, weighted by the estimated effect sizes (Euesden et al., 2015; Ge et al., 2019). We used the estimated effect sizes from a GWAS by Marioni et al. including 388,324 individuals, with 67,614 cases - patients and self-report familial history of AD – and 320,710 controls (Marioni et al., 2018). To generate a set of approximately independent SNPs in our sample, linkage disequilibrium (LD) clumping was performed using PLINK (Purcell et al., 2007) on window size of 1000-kb using a pairwise r² cut-

off of 0.2 and a predetermined significance thresholds (*p*-value < 5 10^{-8} , 10^{-6} , 10^{-4} , 0.001, 0.01, 0.05, 0.1, 0.3, 0.5, and 1). Due to the effect of APOE in chromosome 19, we used a more stringent criteria pairwise r^2 cut-off of 0.01 for this chromosome. In addition, we also calculated the PRS using all the variants with no pruning, i.e. no correction for linkage disequilibrium, thereby selecting all SNPs for PRS construction. This procedure yielded a quantitative polygenic score, under each significance threshold, for each individual in our cohort.

507 Height as a negative control

508 From the known and hypothesised biology, we did not expect any a priori association between 509 the sleep phenotypes and a genetic liability for height. Therefore, we included an analysis of 510 polygenic scores for height as a negative control, performing exactly the same association 511 analyses as we did for liability to AD.

512 Actigraphy data collection and analysis

513 Actigraphy data were collected with Actiwatch 4 devices (Cambridge Neurotechnology ltd, UK) worn on the non-dominant arm. Data consisted in the sum of activity counts over 60-second 514 intervals. Data were analyzed with *pyActigraphy* (Version v0.1) (Hammad and Reyt, 2019) which 515 516 implements the computation of state transition probabilities from rest to activity (kRA) (Lim 517 et al., 2013). In order to better reflect sleep fragmentation, this probability was calculated only over sleep periods for each study's participant. The sleep period is defined as the period 518 comprised between the activity offset and onset times, derived from the average 24h activity 519 520 profile. In addition, to mitigate the uncertainty on their exact timing, the offset and onset times were shifted by +15 min and -15min, respectively. 521

522 Statistical Analysis

We employed general linear model (GLM) to test the associations between sleep metrics of interests as a dependent variable and the estimated PRS as an independent variables and age, BMI and TST as covariates. Prior to the analysis, we removed the outliers among the sleep metrics by excluding the samples lying beyond 4 times the standard deviation (the final number of individuals included in each analyses is reported below each dependent variable in the supplementary tables). All analyses were performed in Python.

In this study, we analysed multiple traits and multiple polygenic risk scores (PRS) for association. To control the experiment-wise false positive rate, we estimated the number of independent tests that we performed, and set an experiment-wise p-value threshold accordingly. Since the traits are phenotypically correlated with each other and the PRSs are also correlated, we used the correlation structure to estimate the equivalent number of tests, which is the number of independent tests that would result in the same overall observed variation.

For each correlation matrix of traits and PRS, we performed a singular value 536 decomposition (SVD), ordered the resulting eigenvalues and calculated the sum of all 537 538 eigenvalues. We then calculated the minimum number of linear combination of the traits that 539 resulted in 99% of the variation. For the 5 EEG phenotypic sleep traits this estimate was 5, showing that they are not highly correlated. Likewise, for the 3 non-EEG phenotypic sleep 540 541 traits this estimate was 3. For the 11 PRS for AD and height, the resulting number was 8 and 542 4, respectively, consistent with a higher correlation structure among the multiple height predictors. Therefore, our analyses with the 5 EEG sleep metrics implies a total number of 40 543 544 and 20 tests when confronted to AD-PRS and height-PRS respectively. Hence, for any of our 545 trait-PRS combination to be statistically significant when taken multiple testing into account, 546 the p-value threshold are 0.00125 and 0.0025 for AD and height, respectively. Similarly, our

analyses with SWE in recovery and extension nights and with SWE rebound, each imply 8 tests
and a p-value threshold of p = 0.00625, while our analyses with 3 non-EEG sleep metrics 24
tests and a p-value threshold of p = 0.0021. Additional analyses compared lower and higher
PRS quartile (i.e. 90 individuals with lowest AD PRS and 90 individuals with highest PRS; cf. Fig.
S4) as well as APOE ε4 carriers vs. non carriers (cf. Fig. S5). For these analyses, groups were
compared through t-tests.

553

554 Acknowledgments

555 We thank E. Balteau, C. Borsu, N. Cai, A. Claes, G. Gaggioni, A. Gobalek, B. Herbillon, P. 556 Hawotte, E. Lambot, B. Lauricella, M. Lennertz, J.Q.L. Ly, M. Micho, G. Salmon and A. Shaffii-557 Le Bourdiec for their help in different steps of the study.

558 Funding

559 P.G., M.V., C.S., F.C., C.P. and G.V. are supported by the Fonds de la Recherche Scientifique -560 FNRS-Belgium. The study was supported by the Wallonia-Brussels Federation (Actions de 561 Recherche Concertées - ARC - 09/14-03), WELBIO/Walloon Excellence in Life Sciences and Biotechnology Grant (WELBIO-CR-2010-06E), FNRS-Belgium (FRS-FNRS, F.4513.17 & 562 T.0242.19 & 3.4516.11), University of Liège (ULiège), Fondation Simone et Pierre Clerdent, 563 European Regional Development Fund (Radiomed project), Fonds Léon Fredericq. DJD is 564 supported by the UK Dementia Research Institute (DRI). 565 566 **Competing interests**

567 All authors declare no competing interests.

568 Author contributions

569	Study concept and design: V.M., S.N.A., M.G., D.J.D., P.M., P.M.V. and G.V. Data acquisition:
570	V.M., M.J., C.Me. Data analyses: V.M., E.K., P.G., C.B., M.B., W.C., N.A. and G.V. Interpretation:
571	V.M., E.K., P.G., D.J.D., P.M., P.M.V., G.V. Analyses support: E.S., A.L., C.P., L.Y., E.B., M.E., M.V.,
572	D.C., C.Mo., G.H., C.D., F.C., M.G., C.S. Manuscript draft: V.M., E.K., P.G., D.J.D., P.M., P.M.V.,
573	G.V. Revised manuscript: all authors.

574 575

576 References

577 Altshuler DL, Durbin RM, Abecasis GR, Bentley DR, Chakravarti A, Clark AG, Collins FS, De La Vega FM, 578 Donnelly P, Egholm M, Flicek P, Gabriel SB, Gibbs RA, Knoppers BM, Lander ES, Lehrach H, Mardis 579 ER, McVean GA, Nickerson DA, Peltonen L, Schafer AJ, Sherry ST, Wang Jun, Wilson RK, Deiros D, 580 Metzker M, Muzny D, Reid J, Wheeler D, Wang SJ, Li J, Jian M, Li G, Li R, Liang H, Tian G, Wang B, 581 Wang Jian, Wang W, Yang H, Zhang X, Zheng Huisong, Ambrogio L, Bloom T, Cibulskis K, Fennell 582 TJ, Jaffe DB, Shefler E, Sougnez CL, Bentley IDR, Gormley N, Humphray S, Kingsbury Z, Koko-583 Gonzales P, Stone J, Mc Kernan KJ, Costa GL, Ichikawa JK, Lee CC, Sudbrak R, Borodina TA, Dahl 584 A, Davydov AN, Marguardt P, Mertes F, Nietfeld W, Rosenstiel P, Schreiber S, Soldatov A V., 585 Timmermann B, Tolzmann M, Affourtit J, Ashworth D, Attiya S, Bachorski M, Buglione E, Burke A, Caprio A, Celone C, Clark S, Conners D, Desany B, Gu L, Guccione L, Kao K, Kebbel A, Knowlton J, 586 587 Labrecque M, McDade L, Mealmaker C, Minderman M, Nawrocki A, Niazi F, Pareja K, Ramenani 588 R, Riches D, Song W, Turcotte C, Wang S, Dooling D, Fulton L, Fulton R, Weinstock G, Burton J, 589 Carter DM, Churcher C, Coffey Alison, Cox A, Palotie A, Quail M, Skelly T, Stalker J, Swerdlow HP, 590 Turner D, De Witte A, Giles S, Bainbridge M, Challis D, Sabo A, Yu F, Yu J, Fang X, Guo X, Li Yingrui, 591 Luo R, Tai S, Wu H, Zheng Hancheng, Zheng X, Zhou Y, Marth GT, Garrison EP, Huang W, Indap A, 592 Kural D, Lee WP, Leong WF, Quinlan AR, Stewart C, Stromberg MP, Ward AN, Wu J, Lee C, Mills 593 RE, Shi X, Daly MJ, DePristo MA, Ball AD, Banks E, Browning BL, Garimella K V., Grossman SR, 594 Handsaker RE, Hanna M, Hartl C, Kernytsky AM, Korn JM, Li H, Maguire JR, McKenna A, Nemesh 595 JC, Philippakis AA, Poplin RE, Price A, Rivas MA, Sabeti PC, Schaffner SF, Shlyakhter IA, Cooper DN, 596 Ball E V., Mort M, Phillips AD, Stenson PD, Sebat J, Makarov V, Ye Kenny, Yoon SC, Bustamante 597 CD, Boyko A, Degenhardt J, Gravel S, Gutenkunst RN, Kaganovich M, Keinan A, Lacroute P, Ma X, 598 Reynolds A, Clarke L, Cunningham F, Herrero J, Keenen S, Kulesha E, Leinonen R, McLaren WM, 599 Radhakrishnan R, Smith RE, Zalunin V, Korbel JO, Stütz AM, Humphray IS, Bauer M, Cheetham RK, 600 Cox T, Eberle M, James T, Kahn S, Murray L, Ye Kai, Fu Y, Hyland FCL, Manning JM, Stephen FM, 601 Peckham HE, Sakarya O, Sun YA, Tsung EF, Mark AB, Konkel MK, Walker JA, Albrecht MW,

602 Amstislavskiy VS, Herwig R, Parkhomchuk D V., Agarwala R, Khouri HM, Morgulis AO, Paschall JE, 603 Phan LD, Rotmistrovsky KE, Sanders RD, Shumway MF, Xiao C, Gil AM, Auton A, Igbal Z, Lunter G, 604 Marchini JL, Moutsianas L, Myers S, Tumian A, Knight J, Winer R, Craig DW, Beckstrom-Sternberg 605 SM, Christoforides A, Kurdoglu AA, Pearson J V., Sinari SA, Tembe WD, Haussler D, Hinrichs AS, 606 Katzman SJ, Kern A, Kuhn RM, Przeworski M, Hernandez RD, Howie B, Kelley JL, Melton SC, Li Yun, 607 Anderson P, Blackwell T, Chen W, Cookson WO, Ding J, Kang HM, Lathrop M, Liang L, Moffatt MF, 608 Scheet P, Sidore C, Snyder Matthew, Zhan X, Zöllner S, Awadalla P, Casals F, Idaghdour Y, Keebler 609 J, Stone EA, Zilversmit M, Jorde L, Xing J, Eichler EE, Aksay G, Alkan C, Hajirasouliha I, Hormozdiari 610 F, Kidd JM, CenkSahinalp S, Sudmant PH, Chen K, Chinwalla A, Ding L, Koboldt DC, McLellan MD, 611 Wallis JW, Wendl MC, Zhang Q, Albers CA, Ayub Q, Balasubramaniam S, Barrett JC, Chen Y, Conrad DF, Danecek P, Dermitzakis ET, Hu M, Huang N, Matt EH, Jin H, Jostins L, Keane TM, Quang Le S, 612 613 Lindsay S, Long Q, MacArthur DG, Montgomery SB, Parts L, Chris Tyler-Smith, Walter K, Zhang Y, 614 Gerstein MB, Snyder Michael, Abyzov A, Balasubramanian S, Bjornson R, Grubert F, Habegger L, 615 Haraksingh R, Khurana E, Lam HYK, Leng J, Mu XJ, Urban AE, Zhang Z, McCarroll SA, Zheng-Bradley 616 X, Batzer MA, Hurles ME, Du J, Jee J, Coafra C, Dinh H, Kovar C, Lee S, Nazareth L, Wilkinson J, 617 Coffey Allison, Scott C, Tyler-Smith C, Gharani N, Kaye JS, Kent A, Li T, McGuire AL, Ossorio PN, 618 Rotimi CN, Su Y, Toji LH, Felsenfeld AL, McEwen JE, Abdallah A, Juenger CR, Clemm NC, Duncanson 619 A, Green ED, Guyer MS, Peterson JL. 2010. A map of human genome variation from population-620 scale sequencing. Nature 467:1061–1073. doi:10.1038/nature09534

Beck AT, Steer RA, G. GM. 1988. Psychometric Properties of the Beck Depression Inventory: Twentyfive years of evaluation. *Clin Psychol Rev* 8:77–100. doi:https://doi.org/10.1016/02727358(88)90050-5

- Bero AW, Bauer AQ, Stewart FR, White BR, Cirrito JR, Raichle ME, Culver JP, Holtzman DM. 2012.
 Bidirectional relationship between functional connectivity and amyloid-β deposition in mouse
 brain. *J Neurosci* 32:4334–4340. doi:10.1523/JNEUROSCI.5845-11.2012
- Bero AW, Yan P, Roh JH, Cirrito JR, Stewart FR, Raichle ME, Lee JM, Holtzman DM. 2011. Neuronal
 activity regulates the regional vulnerability to amyloid-ß deposition. *Nat Neurosci* 14:750–756.
 doi:10.1038/nn.2801
- 630 Berthomier C, Muto V, Schmidt C, Vandewalle G, Jaspar M, Devillers J, Gaggioni G, Chellappa SL, Meyer
- 631 C, Phillips C, Salmon E, Berthomier P, Prado J, Benoit O, Bouet R, Brandewinder M, Mattout J,
- 632 Maquet P. 2020. Exploring scoring methods for research studies : Accuracy and variability of 633 visual and automated sleep scoring 1–11. doi:10.1111/jsr.12994
- Braak H, Del Tredici K. 2015. The preclinical phase of the pathological process underlying sporadic
 Alzheimer's disease. *Brain* 138:2814–2833. doi:10.1093/brain/awv236
- Braak H, Del Tredici K. 2011. The pathological process underlying Alzheimer's disease in individuals

- 637 under thirty. Acta Neuropathol **121**:171–181. doi:10.1007/s00401-010-0789-4
- Branger P, Arenaza-Urquijo EM, Tomadesso C, Mézenge F, André C, de Flores R, Mutlu J, de La Sayette
- V, Eustache F, Chételat G, Rauchs G. 2016. Relationships between sleep quality and brain volume,
 metabolism, and amyloid deposition in late adulthood. *Neurobiol Aging* 41:107–114.

641 doi:10.1016/j.neurobiolaging.2016.02.009

- Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ. 1989. The Pittsburgh sleep quality index: A
 new instrument for psychiatric practice and research. *Psychiatry Res* 28:193–213.
 doi:10.1016/0165-1781(89)90047-4
- 645 Carrier J, Viens I, Poirier G, Robillard R, Lafortune M, Vandewalle G, Martin N, Barakat M, Paquet J,
 646 Filipini D. 2011. Sleep slow wave changes during the middle years of life. *Eur J Neurosci* 33:758–

647 766. doi:10.1111/j.1460-9568.2010.07543.x

- Chai X, Dage JL, Citron M. 2012. Constitutive secretion of tau protein by an unconventional mechanism.
 Neurobiol Dis 48:356–366. doi:10.1016/j.nbd.2012.05.021
- 650 Crimins JL, Rocher AB, Luebke JI. 2012. Electrophysiological changes precede morphological changes
- to frontal cortical pyramidal neurons in the rTg4510 mouse model of progressive tauopathy. *Acta Neuropathol* 124:777–95. doi:10.1007/s00401-012-1038-9
- Dash MB, Douglas CL, Vyazovskiy V V., Cirelli C, Tononi G. 2009. Long-Term Homeostasis of Extracellular
 Glutamate in the Rat Cerebral Cortex across Sleep and Waking States. *J Neurosci* 29:620–629.
 doi:10.1523/JNEUROSCI.5486-08.2009
- DeVos SL, Goncharoff DK, Chen G, Kebodeaux CS, Yamada K, Stewart FR, Schuler DR, Maloney SE,
 Wozniak DF, Rigo F, Bennett CF, Cirrito JR, Holtzman DM, Miller TM. 2013. Antisense Reduction
 of Tau in Adult Mice Protects against Seizures. *J Neurosci* 33:12887–12897.
 doi:10.1523/JNEUROSCI.2107-13.2013
- Dijk D-J, Landolt H-P. 2019. Sleep Physiology, Circadian Rhythms, Waking Performance and the
 Development of Sleep-Wake TherapeuticsHandbook of Experimental Pharmacology. Springer,
 Berlin, Heidelberg. pp. 1–41. doi:10.1007/164_2019_243
- Dijk DJ, Czeisler C a. 1995. Contribution of the circadian pacemaker and the sleep homeostat to sleep
 propensity, sleep structure, electroencephalographic slow waves, and sleep spindle activity in
 humans. J Neurosci 15:3526–3538.
- Dudbridge F. 2013. Power and Predictive Accuracy of Polygenic Risk Scores. *PLoS Genet* 9:e1003348.
 doi:10.1371/journal.pgen.1003348
- Ertekin-Taner N. 2010. Genetics of Alzheimer disease in the pre- and post-GWAS era. *Alzheimer's Res Ther*. doi:10.1186/alzrt26
- Escott-Price V, Sims R, Bannister C, Harold D, Vronskaya M, Majounie E, Badarinarayan N, Morgan K,
 Passmore P, Holmes C, Powell J, Brayne C, Gill M, Mead S, Goate A, Cruchaga C, Lambert JC, Van

- Duijn C, Maier W, Ramirez A, Holmans P, Jones L, Hardy J, Seshadri S, Schellenberg GD, Amouyel
- 673 P, Williams J. 2015. Common polygenic variation enhances risk prediction for Alzheimer's disease.
- 674 Brain **138**:3673–3684. doi:10.1093/brain/awv268
- Ettore E, Bakardjian H, Solé M, Levy Nogueira M, Habert M-O, Gabelle A, Dubois B, Robert P, David R.
 2019. Relationships between objectives sleep parameters and brain amyloid load in subjects at
- risk to Alzheimer's disease: the INSIGHT-preAD Study. *Sleep*. doi:10.1093/sleep/zsz137
- Euesden J, Lewis CM, O'Reilly PF. 2015. PRSice: Polygenic Risk Score software. *Bioinformatics* 31:1466–
 8. doi:10.1093/bioinformatics/btu848
- Fein JA, Sokolow S, Miller CA, Vinters H V, Yang F, Cole GM, Gylys KH. 2008. Co-localization of amyloid
 beta and tau pathology in Alzheimer's disease synaptosomes. *Am J Pathol* 172:1683–92.
 doi:10.2353/ajpath.2008.070829
- Gatz M, Reynolds CA, Fratiglioni L, Johansson B, Mortimer JA, Berg S, Fiske A, Pedersen NL. 2006. Role
 of genes and environments for explaining Alzheimer disease. *Arch Gen Psychiatry* 63:168–174.
 doi:10.1001/archpsyc.63.2.168
- Ge T, Chen C-Y, Ni Y, Feng Y-CA, Smoller JW. 2019. Polygenic prediction via Bayesian regression and
 continuous shrinkage priors. *Nat Commun* 10:1776. doi:10.1038/s41467-019-09718-5
- Hall AM, Throesch BT, Buckingham SC, Markwardt SJ, Peng Y, Wang Q, Hoffman DA, Roberson ED.
 2015. Tau-dependent Kv4.2 depletion and dendritic hyperexcitability in a mouse model of
 Alzheimer's disease. *J Neurosci* 35:6221–6230. doi:10.1523/JNEUROSCI.2552-14.2015
- 691 Hammad G, Reyt M. 2019. ghammad/pyActigraphy: Actigraphy made simple!692 doi:10.5281/ZENODO.2537921
- Hefti K, Holst SC, Sovago J, Bachmann V, Buck A, Ametamey SM, Scheidegger M, Berthold T, GomezMancilla B, Seifritz E, Landolt HP. 2013. Increased metabotropic glutamate receptor subtype 5
 availability in human brain after one night without sleep. *Biol Psychiatry* 73:161–168.
 doi:10.1016/j.biopsych.2012.07.030
- Holth JK, Bomben VC, Reed JG, Inoue T, Younkin L, Younkin SG, Pautler RG, Botas J, Noebels JL. 2013.
 Tau Loss Attenuates Neuronal Network Hyperexcitability in Mouse and Drosophila Genetic
 Models of Epilepsy. *J Neurosci* 33:1651–1659. doi:10.1523/jneurosci.3191-12.2013
- 700 Holth JK, Fritschi SK, Wang C, Pedersen NP, Cirrito JR, Mahan TE, Finn MB, Manis M, Geerling JC, Fuller
- PM, Lucey BP, Holtzman DM. 2019. The sleep-wake cycle regulates brain interstitial fluid tau in
 mice and CSF tau in humans. *Science (80-)* eaav2546. doi:10.1126/science.aav2546
- Horne JA, Ostberg O. 1976. A self-assessment questionnaire to determine morningness-eveningness
 in human circadian rhythms. *Int J Chronobiol* **4**:97–110.
- Huber R, Mäki H, Rosanova M, Casarotto S, Canali P, Casali AG, Tononi G, Massimini M. 2013. Human
 cortical excitability increases with time awake. *Cereb Cortex* 23:332–338.

- 707 doi:10.1093/cercor/bhs014
- Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, Holtzman DM, Jagust W, Jessen
 F, Karlawish J, Liu E, Molinuevo JL, Montine T, Phelps C, Rankin KP, Rowe CC, Scheltens P, Siemers
- 710 E, Snyder HM, Sperling R, Elliott C, Masliah E, Ryan L, Silverberg N. 2018. NIA-AA Research
- 711 Framework: Toward a biological definition of Alzheimer's disease. *Alzheimer's Dement* **14**:535–
- 712 562. doi:10.1016/j.jalz.2018.02.018
- John, Raven J. 2003. Raven Progressive MatricesHandbook of Nonverbal Assessment. Boston, MA:
 Springer US. pp. 223–237. doi:10.1007/978-1-4615-0153-4 11
- Johns MW. 1991. A new method for measuring daytime sleepiness: The Epworth Sleepiness Scale.
 Sleep 14:540–545. doi:10.1016/j.sleep.2007.08.004
- Ju Y-ES, Ooms SJ, Sutphen C, Macauley SL, Zangrilli MA, Jerome G, Fagan AM, Mignot E, Zempel JM,
 Claassen JAHR, Holtzman DM. 2017. Slow wave sleep disruption increases cerebrospinal fluid
 amyloid-β levels. *Brain* 140:2104–2111. doi:10.1093/brain/awx148
- Klerman EB, Dijk DJ. 2005. Interindividual variation in sleep duration and its association with sleep debt
 in young adults. *Sleep* 28:1253–1259. doi:10.1093/sleep/28.10.1253
- Lim ASP, Kowgier M, Yu L, Buchman AS, Bennett DA. 2013. Sleep Fragmentation and the Risk of Incident
 Alzheimer's Disease and Cognitive Decline in Older Persons. *Sleep* 36:1027–1032.
 doi:10.5665/sleep.2802
- Lucey BP, McCullough A, Landsness EC, Toedebusch CD, McLeland JS, Zaza AM, Fagan AM, McCue L,
 Xiong C, Morris JC, Benzinger TLS, Holtzman DM. 2019. Reduced non–rapid eye movement sleep
 is associated with tau pathology in early Alzheimer's disease. *Sci Transl Med* 11:eaau6550.
 doi:10.1126/SCITRANSLMED.AAU6550
- Ly JQM, Gaggioni G, Chellappa SL, Papachilleos S, Brzozowski A, Borsu C, Rosanova M, Sarasso S,
 Middleton B, Luxen A, Archer SN, Phillips C, Dijk D-J, Maquet P, Massimini M, Vandewalle G. 2016.
 Circadian regulation of human cortical excitability. *Nat Commun* 7:11828.
- 732 doi:10.1038/ncomms11828
- 733 Mander BA, Marks SM, Vogel JW, Rao V, Lu B, Saletin JM, Ancoli-Israel S, Jagust WJ, Walker MP. 2015.
- β-amyloid disrupts human NREM slow waves and related hippocampus-dependent memory
 consolidation. *Nat Neurosci* 18:1051–1057. doi:10.1038/nn.4035
- Marden JR, Mayeda ER, Walter S, Vivot A, Tchetgen EJT, Kawachi I, Glymour MM. 2016. Using an 736 737 Alzheimer disease polygenic risk score to predict memory decline in black and white Americans of 738 over 14 years follow-up. Alzheimer Dis Assoc Disord **30**:195–202. 739 doi:10.1097/WAD.00000000000137
- Marioni RE, Harris SE, Zhang Q, McRae AF, Hagenaars SP, Hill WD, Davies G, Ritchie CW, Gale CR, Starr
 JM, Goate AM, Porteous DJ, Yang J, Evans KL, Deary IJ, Wray NR, Visscher PM. 2018. GWAS on

- family history of Alzheimer's disease. *Transl Psychiatry* **8**:99. doi:10.1038/s41398-018-0150-6
- Martiskainen H, Helisalmi S, Viswanathan J, Kurki M, Hall A, Herukka SK, Sarajärvi T, Natunen T,
 Kurkinen KMA, Huovinen J, Mäkinen P, Laitinen M, Koivisto AM, Mattila KM, Lehtimäki T, Remes
 AM, Leinonen V, Haapasalo A, Soininen H, Hiltunen M. 2015. Effects of Alzheimer's disease associated risk loci on cerebrospinal fluid biomarkers and disease progression: A polygenic risk
- 747 score approach. *J Alzheimer's Dis* **43**:565–573. doi:10.3233/JAD-140777
- Mather M, Harley CW. 2016. The Locus Coeruleus: Essential for Maintaining Cognitive Function and
 the Aging Brain. *Trends Cogn Sci* 20:214–26. doi:10.1016/j.tics.2016.01.001
- Mondragón-Rodríguez S, Trillaud-Doppia E, Dudilot A, Bourgeois C, Lauzon M, Leclerc N, Boehm J,
 Mondragon-Rodriguez S, Trillaud-Doppia E, Dudilot A, Bourgeois C, Lauzon M, Leclerc N, Boehm
 J, Mondragón-Rodríguez S, Trillaud-Doppia E, Dudilot A, Bourgeois C, Lauzon M, Leclerc N, Boehm
 J. 2012. Interaction of endogenous tau protein with synaptic proteins is regulated by N-methyl D-aspartate receptor-dependent tau phosphorylation. J Biol Chem 287:32040–32053.
- doi:10.1074/jbc.M112.401240
 Mormino EC, Sperling RA, Holmes AJ, Buckner RL, De Jager PL, Smoller JW, Sabuncu MR. 2016.
 Polygenic risk of Alzheimer disease is associated with early- and late-life processes. *Neurology*
- 758 **87**:481–488. doi:10.1212/WNL.00000000002922
- 759 Musiek ES, Holtzman DM. 2015. Three dimensions of the amyloid hypothesis: Time, space and
 760 "wingmen." *Nat Neurosci*. doi:10.1038/nn.4018
- Nilsen LH, Rae C, Ittner LM, Götz J, Sonnewald U. 2013. Glutamate metabolism is impaired in transgenic
 mice with tau hyperphosphorylation. *J Cereb Blood Flow Metab* 33:684–91.
 doi:10.1038/jcbfm.2012.212
- Norton S, Matthews FE, Barnes DE, Yaffe K, Brayne C. 2014. Potential for primary prevention of
 Alzheimer's disease: An analysis of population-based data. *Lancet Neurol* 13:788–794.
 doi:10.1016/S1474-4422(14)70136-X
- Oddo S, Caccamo A, Shepherd JD, Murphy MPP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari
 Y, LaFerla FM. 2003. Triple-Transgenic Model of Alzheimer's Disease with Plaques and Tangles.
 Neuron 39:409–421. doi:10.1016/S0896-6273(03)00434-3
- Ooms S, Overeem S, Besse K, Rikkert MO, Verbeek M, Claassen J a HR. 2014. Effect of 1 Night of Total
 Sleep Deprivation on Cerebrospinal Fluid β-Amyloid 42 in Healthy Middle-Aged Men: A
 Randomized Clinical Trial. *JAMA Neurol* **71**:971–977. doi:10.1001/jamaneurol.2014.1173
- 773 Pase MP, Himali JJ, Grima NA, Beiser AS, Satizabal CL, Aparicio HJ, Thomas RJ, Gottlieb DJ, Auerbach
- SH, Seshadri S. 2017. Sleep architecture and the risk of incident dementia in the community.
 Neurology 89:10.1212/WNL.00000000004373. doi:10.1212/WNL.0000000004373
- Polydoro M, Dzhala VI, Pooler AM, Nicholls SB, McKinney AP, Sanchez L, Pitstick R, Carlson GA, Staley

- KJ, Spires-Jones TL, Hyman BT. 2014. Soluble pathological tau in the entorhinal cortex leads to
 presynaptic deficits in an early Alzheimer's disease model. *Acta Neuropathol* 127:257–270.
 doi:10.1007/s00401-013-1215-5
- Pooler AM, Noble W, Hanger DP. 2014. A role for tau at the synapse in Alzheimer's disease
 pathogenesis. *Neuropharmacology* 76:1–8. doi:10.1016/j.neuropharm.2013.09.018
- 782 Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MAR, Bender D, Maller J, Sklar P, de Bakker PIW,
- Daly MJ, Sham PC. 2007. PLINK: a tool set for whole-genome association and population-based
 linkage analyses. *Am J Hum Genet* 81:559–75. doi:10.1086/519795
- Roh JH, Huang Y, Bero a. W, Kasten T, Stewart FR, Bateman RJ, Holtzman DM. 2012. Disruption of the
 Sleep-Wake Cycle and Diurnal Fluctuation of β-Amyloid in Mice with Alzheimer's Disease
 Pathology. *Sci Transl Med* 4:150ra122-150ra122. doi:10.1126/scitranslmed.3004291
- Sabuncu MR, Buckner RL, Smoller JW, Lee PH, Fischl B, Sperling RA. 2012. The association between a
 polygenic Alzheimer score and cortical thickness in clinically normal subjects. *Cereb Cortex* 22:2653–2661. doi:10.1093/cercor/bhr348
- Santoro ML, Ota V, de Jong S, Noto C, Spindola LM, Talarico F, Gouvea E, Lee SH, Moretti P, Curtis C,
 Patel H, Newhouse S, Carvalho CM, Gadelha A, Cordeiro Q, Bressan RA, Belangero SI, Breen G.
 2018. Polygenic risk score analyses of symptoms and treatment response in an antipsychoticnaive first episode of psychosis cohort. *Transl Psychiatry* 8:174. doi:10.1038/s41398-018-0230-7
- 795 Scammell TE, Arrigoni E, Lipton JO. 2017. Neural Circuitry of Wakefulness and Sleep. *Neuron*.
 796 doi:10.1016/j.neuron.2017.01.014
- Scheltens P, Blennow K, Breteler MMB, de Strooper B, Frisoni GB, Salloway S, Van der Flier WM. 2016.
 Alzheimer's disease. *Lancet* 388:505–517. doi:10.1016/S0140-6736(15)01124-1
- Schmidt C, Peigneux P, Cajochen C. 2012. Age-related changes in sleep and circadian rhythms: Impact
 on cognitive performance and underlying neuroanatomical networks. *Front Neurol* JUL:118.
 doi:10.3389/fneur.2012.00118
- Schultz MK, Gentzel R, Usenovic M, Gretzula C, Ware C, Parmentier-Batteur S, Schachter JB, Zariwala
 HA. 2018. Pharmacogenetic neuronal stimulation increases human tau pathology and transsynaptic spread of tau to distal brain regions in mice. *Neurobiol Dis* 118:161–176.
 doi:10.1016/j.nbd.2018.07.003
- 806 Skorucak J, Arbon EL, Dijk D-J, Achermann P. 2018. Response to chronic sleep restriction, extension,
- and total sleep deprivation in humans: adaptation or preserved sleep homeostasis? *Sleep* 1–27.
 doi:10.1093/ntr/ntx198/4104547/Differences-in-adolescent-e-cigarette-and
- Sleegers K, Bettens K, De Roeck A, Van Cauwenberghe C, Cuyvers E, Verheijen J, Struyfs H, Van Dongen
 J, Vermeulen S, Engelborghs S, Vandenbulcke M, Vandenberghe R, De Deyn PP, Van Broeckhoven
- 811 C, BELNEU consortium. 2015. A 22-single nucleotide polymorphism Alzheimer's disease risk score

- 812 correlates with family history, onset age, and cerebrospinal fluid Aβ42. Alzheimers Dement
- 813 **11**:1452–60. doi:10.1016/j.jalz.2015.02.013
- Steriade M, Amzica F. 1998. Slow sleep oscillation, rhythmic K-complexes, and their paroxysmal
 developments. *J Sleep Res* 7:30–35. doi:10.1046/j.1365-2869.7.s1.4.x
- Svetnik V, Snyder ES, Ma J, Tao P, Lines C, Herring WJ. 2017. EEG spectral analysis of NREM sleep in a
 large sample of patients with insomnia and good sleepers: effects of age, sex and part of the
 night. J Sleep Res 26:92–104. doi:10.1111/jsr.12448
- Sydow A, Van der Jeugd A, Zheng F, Ahmed T, Balschun D, Petrova O, Drexler D, Zhou L, Rune G,
 Mandelkow E, D'Hooge R, Alzheimer C, Mandelkow E-M. 2011. Tau-induced defects in synaptic
 plasticity, learning, and memory are reversible in transgenic mice after switching off the toxic Tau
 mutant. J Neurosci 31:2511–25. doi:10.1523/JNEUROSCI.5245-10.2011
- Thal D, Rüb U, Orantes M, Braak H. 2002. Phases of A beta-deposition in the human brain and its relevance for the development af AD. *Neurology* **58**:1791–1800.
- Tononi G, Cirelli C. 2014. Sleep and the Price of Plasticity: From Synaptic and Cellular Homeostasis to
 Memory Consolidation and Integration. *Neuron* 81:12–34. doi:10.1016/j.neuron.2013.12.025
- 827 Van der Jeugd A, Hochgräfe K, Ahmed T, Decker JM, Sydow A, Hofmann A, Wu D, Messing L, Balschun
- D, D'Hooge R, Mandelkow E-M, Jochen A, Van der Jeugd A, Hochgräfe K, Ahmed T, Decker JM,
- 829 Sydow A, Hofmann A, Wu D, Messing L, Balschun D, D'Hooge R, Mandelkow E-M, Jochen A. 2012.
- 830 Cognitive defects are reversible in inducible mice expressing pro-aggregant full-length human
- 831 Tau. Acta Neuropathol **123**:787–805. doi:10.1007/s00401-012-0987-3
- Van Egroo M, Narbutas J, Chylinski D, Villar González P, Maquet P, Salmon E, Bastin C, Collette F,
 Vandewalle G. 2019. Sleep–wake regulation and the hallmarks of the pathogenesis of Alzheimer's
 disease. *Sleep* 42. doi:10.1093/sleep/zsz017
- Viola AU, Archer SN, James LMM, Groeger JA, Lo JCY, Skene DJ, von Schantz M, Dijk DJ. 2007. PER3
 Polymorphism Predicts Sleep Structure and Waking Performance. *Curr Biol* 17:613–618.
 doi:10.1016/j.cub.2007.01.073
- 838 Wallant DC t., Muto V, Gaggioni G, Jaspar M, Chellappa SL, Meyer C, Vandewalle G, Maquet P, Phillips
- C. 2016. Automatic artifacts and arousals detection in whole-night sleep EEG recordings. J
 Neurosci Methods 258:124–133. doi:10.1016/j.jneumeth.2015.11.005
- 841 Yamada K, Holth JK, Liao F, Stewart FR, Mahan TE, Jiang H, Cirrito JR, Patel TK, Hochgräfe K, Mandelkow
- E-M, Holtzman DM. 2014. Neuronal activity regulates extracellular tau in vivo. J Exp Med
 211:387–393. doi:10.1084/jem.20131685
- Yengo L, Sidorenko J, Kemper KE, Zheng Z, Wood AR, Weedon MN, Frayling TM, Hirschhorn J, Yang J,
- 845 Visscher PM. 2018. Meta-analysis of genome-wide association studies for height and body mass
- index in ~700000 individuals of European ancestry. *Hum Mol Genet*. doi:10.1093/hmg/ddy271



848 Figures and Tables

849

850



852

853 **Figure 1: Overview of the protocol.**

854

855 Following 3 weeks of regular sleep at habitual times, 363 healthy young men aged ~22 y

complete a 7-day protocol (displayed for a participant sleeping from 11PM to 7PM).

857 Adaptation/screening and baseline nights were scheduled at habitual sleep-wake times.

858 Extension nights consisted of a 12h sleep opportunity centred around habitual sleep mid-

point. Nap consisted of an afternoon 4h sleep opportunity. The "Before" (sleep deprivation)

and recovery nights (from sleep deprivation) consisted of an 8h and 12h sleep opportunity

respectively, all starting at habitual sleep time. Following the "before" night, volunteers
 completed a 40h sleep deprivation protocol under strictly controlled constant routine

conditions in dim light. Sleep periods included in the current analyses are in bold and italic.



864

865

Figure 2: Associations between Polygenic Risk Score (PRS) for AD and baseline night sleep 866 metrics. 867

A. Statistical outcomes of GLMs with five sleep metrics of interest vs. AD PRS from 868 conservative ($p < 5x10^{-8}$) p-value threshold to using all SNPs. GLMs are corrected for age, BMI 869 and total sleep time (TST). Negative log transformation of p-values of the associations are 870 presented on the vertical axis. Horizontal lines in A and D indicate different p-values 871 872 thresholds: light blue = .05 (uncorrected); orange= .01 (corrected for 5 sleep metrics); red = 0.00125 (experiment-wise correction; see methods). 873

874 SOL: sleep onset latency; WASO: wake time after sleep onset; DUR REM: duration of REM sleep; arousal: hourly rate of micro-arousal during sleep; SWE: slow wave energy in NREM 875 sleep (0.5-4Hz) 876

B. Positive association between SWE during baseline night and AD PRS including All SNPs. 877

- Spearman correlation r is reported for completeness (r = .12, p = .02), refer to main text Table 878 879 S2 for statistical outputs of GLMs.
- **C**. Negative association between SOL during baseline night and AD PRS for p < 0.3. Spearman 880
- correlation r is reported for completeness (r = -.11, p = .03), refer to main text Table S2 for 881 statistical outputs of GLMs. 882
- 883 **D.** GLMs including SWE separated in the slower (SO-SWE; 0.5-1Hz) and faster (FO-SWE; 1.25-
- 4Hz) frequency range from conservative p-value thresholds to using all SNPs. Horizontal blue 884
- line indicate p = 0.05 significance level. GLMs are corrected for age, BMI and TST. Refer to 885
- 886 main text Table S3 for statistical outputs of GLMs.



887

Figure 3: Associations between Polygenic Risk Score (PRS) for AD and slow wave energy
 (SWE) during recovery and extension nights and with SWE rebound.

890

A. Statistical outcomes of GLMs with SWE (0.5-4Hz) in the recovery (REC) and extension (EXT) nights and with SWE rebound (REC/BAS) vs. AD PRS from conservative ($p < 5x10^{-8}$) to inclusive (p < 1) p-value level and using all SNPs. SWE rebound consist in the ratio between SWE in the first hour of sleep of recovery and baseline nights. GLMs are corrected for age and BMI, and TST for REC and EXT. Negative log transformation of p-values of the associations are presented on the vertical axis. Horizontal lines indicate different p-values thresholds: light blue = .05 (uncorrected); red = 0.00625 (experiment-wise correction; see methods).

898 **B.** Positive association between SWE during recovery night and AD PRS at p < 1. Spearman 899 correlation r is reported for completeness (r = .01, p = .06), srefer to main text Table S4 for 900 statistical outputs of GLMs.

901 C. Positive association between SWE during recovery and SWE rebound (SWE REC/BAS):
 902 Spearman correlation r = .36, p < .001.



Figure 4: Associations between Polygenic Risk Score (PRS) for AD and non-EEG sleep metrics.

A. Statistical outcomes of GLMs with actimetry-assessed sleep fragmentation (kRA), subjective sleep quality (Sleep-qual) and subjective daytime sleepiness (Day-sleepiness) vs. AD PRS from conservative ($p < 5x10^{-8}$) to inclusive (p < 1) p-value thresholds and using all SNPs. GLMs are corrected for age and BMI. Negative log transformation of p-values of the associations are presented on the vertical axis. Horizontal lines indicate different p-values: light blue = .05 (uncorrected); orange= .016 (corrected for 3 sleep metrics); red = 0.002 (experiment-wise correction).

913 **B.** Positive association between subjective daytime sleepiness and AD PRS at p < 0.05. Linear

regression line shown for display purposes only; refer to main text and Table S5 for statistical

915 outputs of GLMs.

916	Table 1. Sample characteristics	(mean ± SD).
		(····•··· = •= /·

363	
Men	
Caucasian	
22.10 ± 2.73	
180.39 ± 6.70	
22.15 ± 2.31	
123.88 ±	
11.14	
13.33 ± 1.60	
3.00 ± 3.48	
3.46 ± 1.76	
5.94 ± 3.54	
50.11 ± 8.25	
0.10 ± 0.02	
0.10 ± 0.03	
451 ± 41	

917

918 Mood was estimated by the 21-item Beck Depression Inventory II (Beck et al., 1988), sleep

919 quality by the Pittsburgh Sleep Quality Index (PSQI) (Buysse et al., 1989); daytime sleepiness

920 by the Epworth Sleepiness Scale (ESS)(Johns, 1991); chronotype by the Horne-Östberg

921 questionnaire (Horne and Ostberg, 1976). IQ was estimated using Raven Progressive

922 Matrices (John and Raven, 2003). Rest fragmentation (arbitrary units, a.u.) was estimated as

923 the probability of transition from rest to activity during estimated sleep based on actigraphy

data from the 3 weeks of imposed regular sleep (Hammad and Reyt, 2019; Lim et al., 2013).